Maxion Therapeutics gets $16m Series A Financing

LifeArc Ventures is leading a $16 million (£13 million) Series A financing of Maxion Therapeutics (PDF), together with Monograph Capital and BGF. Put together by industry veteran Dr John McCafferty – founder of Cambridge Antibody Technology (CAT) and co-inventor of antibody phage display, receiving the 2018 Nobel Prize in Chemistry – Maxion Therapeutics aims to revolutionise antibody development for ion channel and GPCR-driven diseases, which so far have been untreatable.